"ARV drugs adverse events, case definition, grading, laboratory diagnosis and treatment monitoring"

A meeting of experts, jointly organized by WHO/HIV and PSM Departments, and the FORUM for HIV Collaborative Research

28-29 February 2008
WHO, Geneva

(D Building, ground floor, Kofi Annan meeting room)

AGENDA

Thursday, 28 February 2008

08.30-09.00	Registration	
Plenary Session 1: Meeting Opening		Chair: Dr H. Hogerzeil, Director HQ/DG/HSS/PSM
09.00-10.00	Welcome address	Dr K. De Cock, Director HQ/HTM/HIV
	Introduction to the meeting.	Dr J. Aberg
	Meeting objectives.	Dr C. Gilks
	Key note speech: Definitions of AE related to ARVs: What are we talking about?	Dr J. Lundgren
	AE related to ARVs : available data from UPSALA	Dr M. Lindquist
10.15-10.30	Coffee Break	
Plenary session 2: Definitions of Adverse Events linked to Antiretroviral Drugs		Chair Dr. P. Munderi Panel: Presenters
10.30-10.50	Overview of current knowledge on adverse effects of ARVs and existing definitions: needs and gaps:	Dr. N. Bakare
10:50-11:15	AE related to ARVs: the cohort perspective.	Dr. C. Williams
	A clinician's perspective on AEs related to ARVs.	Dr. J. Hakim
11:15-11:30	Presentation of MedDRA	Dr. A. Zhao-Wong
11:30-12:15	Introduction to the working group sessions: expected outcomes	Dr. M. Diepart
	Discussion and getting a consensus on definitions : challenges and limits	Dr. D. Coulter
12:15-12.30	Groups constitution*	M. B. Cheng
12.30-13.30	Lunch	
Working groups sessions		
13.30-16.00	Working group sessions: 5 parallel sessions by thematic areas* List of definitions of AE /ARVs Setting methodology and criteria for case definition	
16.00-16.15	Coffee Break	
Plenary session		Chair Dr A. Oto Dodoo Panel: Rapporteurs of working groups
16.15-18.00	Reports by working groups (5 minutes by group) Discussion : reaching a consensus on the list of AE/ARVs definitions and a methodology for setting the case definition	
18.00-18:40	Reception: Cocktail Building D Ground Floor	
19:00	Dinner offered by the Forum for Collaborative Research at "Le Vieux Bois" Av. de la Paix, Genève	

Friday, 29 February 2008

Plenary session 4:		Chair : Dr S. Eholié Panel: Chairs of the working groups Day 1
09:00-9:45	Report of first day; discussion: methodology to identify and manage adverse events linked to ARVs	
Working group sessions		
9:45-10:30	Report of working groups: Work in plenary	
10.30-10:45	Coffee Break	
10.45-12:30	Plenary work ctd: Review of priority listing of adverse events linked to ARVs.	
12:30-13:30	Lunch Break	
Plenary session 5:		Chair: Dr C. Williams Panel: Chairs of the working groups Day 2
14:00-15:30	Plenary work ctd: Meeting consensus	
15.30-16:00	Coffee Break	
Plenary session 6:		Chair Dr H. Nakatani, ADG, HQ/HTM Assistant Panel: Dr Gilks; Dr J Aberg
16:00-17.30	Next steps	Dr. J. Aberg Dr. C. Gilks
17.30	Close meeting	Dr K. De Cock, Director HQ/HTM/HIV Dr H. Hogerzeil, Director HQ/HSS/QSM

Working groups were constituted with representatives from different fields of expertise, cohorts, clinicians, PV specialists.

First day, 5 groups organized around different thematic areas:
1. Blood and lymphatic system disorders; Cardio vascular; Respiratory; General disorders:
2. Skin and subcutaneous tissue; Immune system disorders; Neoplasms benign, malignant and unspecified:
3. Metabolism and nutrition; Gastrointestinal; Hepatobiliary; Renal and urinary disorders:
4. Musculoskeletal and connective tissue; Nervous system; Psychiatric disorders:
5. Reproductive system; Pregnancy; Puerpuerium and perinatal; Congenital and genetic disorders: